 Shares of HTG Molecular Diagnostics NASDAQ:HTGM were flat in after-market trading after the company reported Q2 results.Quarterly Results Earnings per share were up 47.06 year over year to 0.09, which missed the estimate of 0.08.Revenue of 1,963,000 declined by 66.13 from the same period last year, which beat the estimate of 1,790,000.Looking Ahead Earnings guidance hasnt been issued by the company for now.Revenue guidance hasnt been issued by the company for now.Conference Call Details Date: Aug 11, 2020View more earnings on HTGMTime: 04:30 PMET Webcast URL: 52-week high: 1.1952-week low: 0.27Price action over last quarter: Up 46.68Company Description HTG Molecular Diagnostics Inc is a commercial-stage company that develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. Molecular profiling is the collection of information about multiple molecular targets, such as DNA and RNA, also called biomarkers, in a biological sample. Molecular profiling information has many important applications, from basic research to molecular diagnostics in personalized medicine. The company derives revenue from services provided by its VERIO laboratory and sales of the companys automation systems and integrated next-generation sequencing-based HTG EdgeSeq assays. It operates in one segment and its customers are primarily located in the United States and Europe.See more from Benzinga Earnings Scheduled For August 11, 2020 Earnings Preview: HTG Molecular Diagnostics 18 Healthcare Stocks Moving In Tuesdays Pre-Market SessionC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 